• Hyperprolactinemia syndrome in the outpatient practice of an obstetrician-gynecologist (Clinical lecture)

Hyperprolactinemia syndrome in the outpatient practice of an obstetrician-gynecologist (Clinical lecture)

HEALTH OF WOMAN. 2017.9(125):10–16; doi 10.15574/HW.2017.125.10  

Pyrohova V. I., Veresnyuk N. S., Shurpyak S. O.
Lviv national medical University named Danylo Galitsky

The article highlights diagnostic and therapeutic approaches in the syndrome of hyperprolactinemia. General information about the secretion of prolactin, its isoforms, the issues of diagnostic and therapeutic tactics for different genesis of hyperprolactinemia, aspects of monitoring patients, including during pregnancy and breastfeeding, are presented.
Key words: hyperprolactinemia, dopamine, prolactinoma, reproductive health, hyperprolactinemic hypogonadism, cabergoline, pregnancy.

References
1. Andreyeva EN. Khamoshina MB. Rudneva OD. 2012. Prolaktin i molochnyye zhelezy: norma i patologiya. Ginekologiya 14;6:12–16.

2. Artymuk NV. Ustinova TA. Vlasova VV. 2011. Opyt primeneniya Vitex Agnus Castus v komplekse lecheniya patsiyentok s sindromom polikistoznykh yaichnikov. Rossiyskiy vestnik akushera-ginekologa 2:65–68.

3. Veropotvelyan PN. Veropotvelyan NP. Bondarenko AA. 2011. Vliyaniye prolaktina na sostoyaniye molochnykh zhelez. Meditsinskiye aspekty zdorovia zhenshchiny 3/1(43):29–37.

4. Vorotnikova SYu. 2011. Diagnostika i lecheniye giperprolaktinemii: klinicheskiye rekomendatsii Mezhdunarodnogo Endokrinologicheskogo obshchestva. Perevod i kommentarii SYu Vorotnikova. EA Pigarova. LK Dzeranova. Ozhireniye i metabolizm 2:79–94.

5. Vuttke V. Yarri G. Zaydlova-Vuttke D. 2009. Terapevticheskiye vozmozhnosti ekstraktov iz Avramova dereva (VitexAgnuscastus) v ginekologicheskoy praktike. Probl. reproduktsii. 4:53–57.

6. Ovsyannikova TV. Makarov IO. Kamilova DP i dr. 2012. Giperprolaktinemiya: sovremennyye podkhody k diagnostike i lecheniyu. Ginekologiya 13;6:14–17.

7. Dedov II i dr. 2009. Giperprolaktinemiya. Sovremennyye podkhody i staryye problemy. Vestnik reproduktivnogo zdorovia 2(iyun):2–8.

8. Dzeranova LK. Ilovayskaya IA. 2012. Diagnostika i lecheniye giperprolaktinemii: klinicheskiye rekomendatsii Mezhdunarodnogo endokrinologicheskogo obshchestva i vzglyad rossiyskikh ekspertov. Effektivnaya farmakoterapiya 1:2–7.

9. Dzeranova LK. Barnmina II. 2009. Osobennosti diagnostiki i lecheniya giperprolaktinemicheskogo sindroma. Effektivnaya farmakoterapiya v endokrinologii 1:2–7.

10. Dzeranova LK. Vorotnikova SYu. 2013. Kabergolin: 30-letneye edinstvo opyta i doveriya. Rossiyskiy vestnik akushera-ginekologa 13;6:45–49.

11. Ilovayskaya IA. 2012. Sovremennyye predstavleniya o diagnostike i lechenii sindroma giperprolaktinemii. Byulleten VSNTs SO RAMN 3(85);Ch. 1:127–134.

12. Kalinchenko SYu. 2013. Mify i pravda o giperprolaktinemii: izbrannyye lektsii. M. Praktich. meditsina:108.

13. Korneyeva Iye. Ovsyannikova TV. 2009. Diagnostika i lecheniye besplodiya u zhenshchin s funktsionalnoy giperprolaktinemiyey. Vopr. ginekologii. akusherstva i perinatologii 4:54–58.

14. Melnichenko GA. 2007. Giperprolaktinemiya: tridtsatiletnyaya istoriya izucheniya sindroma. Zdorov’ya Ukraїni 10/1.

15. Mokhort TV. Safina MR. 2012. Cindrom giperprolaktinemii: sovremennyye podkhody k diagnostike i lecheniyu. Reproduktivnoye zdorovye. Vostochnaya Evropa 4(22):130–141.

16. Tronko MD, Antipkin YuH, Kaminskyi VV, Tatarchuk TF. 2016. Natsionalnyi konsensus shchodo vedennia patsiientiv iz hiperprolaktynemiieiu. Reproduktyvna endokrynolohiia 4 (30).

17. Tumilovich LG. Gevorkyan MA. 2014. Spravochnik ginekologa-endokrinologa. M. Prakticheskaya meditsina:208.

18. Shishkova VN. 2010. Ozhireniye i giperprolaktinemiya. Consiliummedicum 12;12:3–6.

19. Shilin DE. Adamyan LV. 2010. Kabergolin: 25 let v terapii patologicheskoy giperprolaktinemii. Ginekologiya 12;1:34–39.

20. Crosignani PG. 2012. Management of hyperprolactinemic infertility. Middle East Fertility Society Journal 17:63–69. https://doi.org/10.1016/j.mefs.2012.04.003

21. Hall R, Manski-Nankervist J, Goni N et al. 2006. Fertility outcomes in women with hypopituitarism. Clin. Endocrinology 1:71–74. https://doi.org/10.1111/j.1365-2265.2006.02550.x; PMid:16817822

22. Fernandez A, Karavitaki N, Wass JA. 2010. Prevalence of pituitary adenomas: a communitybased, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.). 72:377–382. https://doi.org/10.1111/j.1365-2265.2009.03667.x; PMid:19650784

23. Freeman ME, Kanyicska B, Lerant A et al. 2000. Prolactin: Structure, Function, and Regulation of Secretion. Physiol Rev. 80;4:1523–1631. https://doi.org/10.1152/physrev.2000.80.4.1523; PMid:11015620

24. Galois S, Kertes G, Somma C. 2005. Clinical expression of big-big prolactin and influence of macroprolactinemia upon immunodiagnostic tests. Actaendocrinol. 1:31–41. https://doi.org/10.4183/aeb.2005.31

25. Gillam MP et al. 2006. Advances in the treatment of prolactinomas. Endocr. Rev. 27:485–534. https://doi.org/10.1210/er.2005-9998; PMid:16705142

26. Glezer А, Bronstein MD. 2012. Approach to the Patient with Persistent Hyperprolactinemia and Negative Sellar Imaging. Clin. Endocrinol. Metab. 97:2211–2216. https://doi.org/10.1210/jc.2011-2976; PMid:22774208

27. Casanueva FF et al. 2006. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.). 65:265–273. https://doi.org/10.1111/j.1365-2265.2006.02562.x; PMid:16886971

28. Hattori N. 2003. Macrprolactinaemia: a new cause of hyperprolactinaemia. J. Pharmacol. Sci. 92;3:171–177. https://doi.org/10.1254/jphs.92.171

29. Klibanski A. 2010. Clinical practice. Prolactinomas. N. Engl. J. Med. 362:1219–1226. https://doi.org/10.1056/NEJMcp0912025; PMid:20357284

30. Lu CC, Hsieh CJ. 2012. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients. Kaohsiung J. Med. Sci. 28;2:94–99. https://doi.org/10.1016/j.kjms.2011.10.030; PMid:22313536

31. Vantckova M, Seidl Z, Hana V et al. 2007. Macroprolactinomas: Retrospective follow up study in the MR imaging and correlation with clinical symptomatology. Neur. Endocrinol. Let. Dec. 28:841–845.

32. Melmed S et al. 2011. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96;2:273–288. https://doi.org/10.1210/jc.2010-1692; PMid:21296991

33. Pinto LP, Hanna FW, Evans LM et al. 2003. The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia. Clinical Endocrinology. 59:580–584. https://doi.org/10.1046/j.1365-2265.2003.01887.x; PMid:14616880

34. Colao A et al. 2007. Predictors of remission of hyperprolactinaemia after long-term with-drawal of cabergoline therapy. Clin. Endocrinol. (Oxf.). 67;3:426–433. https://doi.org/10.1111/j.1365-2265.2007.02905.x; PMid:17573902

35. Lewandowski KC, Gąior-Perczak D, Kowalska A et al. 2012, December 17. Prevalence of macroprolactinaemia in regularly menstruating women with nontoxic goitre or autoimmune thyroid disease. Published online. https://doi.org/10.1186/1756-6614-5-20.

36. Renata S, Auriemma, Ylenia Perone, Antonella Di Sarno et al. 2013. Results of a Single-Center Observational 10-Year Survey Study on Recurrence of Hyperprolactinemia after Pregnancy and Lactation. J. Clin. Endocrinol. Metab. 98(1):372–379. https://doi.org/10.1210/jc.2012-3039; PMid:23162092

37. Hekimsoy Z et al. 2010. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr. J. 57;12:1011–1015. https://doi.org/10.1507/endocrj.K10E-215